Jérôme Côté
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jérôme Côté has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Philippe Sarret
Université de Sherbrooke
6 shared publications - Jean-Michel Longpré
Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Institute de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, Canada
4 shared publications Camille Lagard
Department of Pharmacology-Physiology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada; Institut de Pharmacologie de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC J1H 5N4, Canada
3 shared publicationsMagali Chartier
3 shared publications- Michael Desgagné
Department of Chemistry, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
3 shared publications - Pierre-Luc Boudreault
Université de Sherbrooke
3 shared publications
Latest Publications
- Open Access
- 23 May 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 200, 119551
Improved brain penetration of neurotensin(8–13) via blood-brain barrier shuttle conjugation underlies strong analgesia
- 23 May 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 200, 119551
Open AccessImproved brain penetration of neurotensin(8–13) via blood-brain barrier shuttle conjugation underlies strong analgesia
- Open Access
- 11 May 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 199, 119488
Dual-target opioid/neurotensin ligands drive potent and safer analgesia in vivo
- 11 May 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 199, 119488
Open AccessDual-target opioid/neurotensin ligands drive potent and safer analgesia in vivo
- Open Access
- 31 December 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (4) , 2396-2419
A neurotensin receptor type 1-derived pepducin acts as a biased allosteric modulator to regulate target receptor function
- 31 December 2025
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 16 (4) , 2396-2419
Open AccessA neurotensin receptor type 1-derived pepducin acts as a biased allosteric modulator to regulate target receptor function
- Open Access
- 14 October 2024
- Published by Wiley in Angewandte Chemie
- Vol. 136 (47)
Development of Macrocyclic Neurotensin Receptor Type 2 (NTS2) Opioid‐Free Analgesics
The opioid crisis has highlighted the urgent need to develop non‐opioid alternatives for managing pain, with an effective, safe, and non‐addictive pharmacotherapeutic profile. Using an extensive structure–activity relationship approach, here we have identified a new series of highly selective neurotensin receptor type 2 (NTS2) macrocyclic compounds that exert potent, opioid‐independent analgesia in various experimental pain models. To our knowledge, the constrained macrocycle in which the Ile12 residue of NT(7–12) was substituted by cyclopentylalanine, Pro7 and Pro10 were replaced by allyl‐glycine followed by side‐chain to side‐chain cyclization is the most selective analog targeting NTS2 identified to date (Ki 2.9 nM), showing 30,000‐fold selectivity over NTS1. Of particular importance, this macrocyclic analog is also able to potentiate the analgesic effects of morphine in a dose‐ and time‐dependent manner. Exerting complementary analgesic actions via distinct mechanisms of nociceptive transmission, NTS2‐selective macrocycles can therefore be exploited as opioid‐free analgesics or as opioid‐sparing therapeutics, offering superior pain relief with reduced adverse effects to pain patients.
- 14 October 2024
- Published by Wiley in Angewandte Chemie
- Vol. 136 (47)
Open AccessDevelopment of Macrocyclic Neurotensin Receptor Type 2 (NTS2) Opioid‐Free Analgesics
The opioid crisis has highlighted the urgent need to develop non‐opioid alternatives for managing pain, with an effective, safe, and non‐addictive pharmacotherapeutic profile. Using an extensive structure–activity relationship approach, here we have identified a new series of highly selective neurotensin receptor type 2 (NTS2) macrocyclic compounds that exert potent, opioid‐independent analgesia in various experimental pain models. To our knowledge, the constrained macrocycle in which the Ile12 residue of NT(7–12) was substituted by cyclopentylalanine, Pro7 and Pro10 were replaced by allyl‐glycine followed by side‐chain to side‐chain cyclization is the most selective analog targeting NTS2 identified to date (Ki 2.9 nM), showing 30,000‐fold selectivity over NTS1. Of particular importance, this macrocyclic analog is also able to potentiate the analgesic effects of morphine in a dose‐ and time‐dependent manner. Exerting complementary analgesic actions via distinct mechanisms of nociceptive transmission, NTS2‐selective macrocycles can therefore be exploited as opioid‐free analgesics or as opioid‐sparing therapeutics, offering superior pain relief with reduced adverse effects to pain patients.
- Open Access
- 14 October 2024
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 63 (47) , e202405941
Development of Macrocyclic Neurotensin Receptor Type 2 (NTS2) Opioid‐Free Analgesics
The opioid crisis has highlighted the urgent need to develop non‐opioid alternatives for managing pain, with an effective, safe, and non‐addictive pharmacotherapeutic profile. Using an extensive structure–activity relationship approach, here we have identified a new series of highly selective neurotensin receptor type 2 (NTS2) macrocyclic compounds that exert potent, opioid‐independent analgesia in various experimental pain models. To our knowledge, the constrained macrocycle in which the Ile12 residue of NT(7–12) was substituted by cyclopentylalanine, Pro7 and Pro10 were replaced by allyl‐glycine followed by side‐chain to side‐chain cyclization is the most selective analog targeting NTS2 identified to date (Ki 2.9 nM), showing 30,000‐fold selectivity over NTS1. Of particular importance, this macrocyclic analog is also able to potentiate the analgesic effects of morphine in a dose‐ and time‐dependent manner. Exerting complementary analgesic actions via distinct mechanisms of nociceptive transmission, NTS2‐selective macrocycles can therefore be exploited as opioid‐free analgesics or as opioid‐sparing therapeutics, offering superior pain relief with reduced adverse effects to pain patients.
- 14 October 2024
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 63 (47) , e202405941
Open AccessDevelopment of Macrocyclic Neurotensin Receptor Type 2 (NTS2) Opioid‐Free Analgesics
The opioid crisis has highlighted the urgent need to develop non‐opioid alternatives for managing pain, with an effective, safe, and non‐addictive pharmacotherapeutic profile. Using an extensive structure–activity relationship approach, here we have identified a new series of highly selective neurotensin receptor type 2 (NTS2) macrocyclic compounds that exert potent, opioid‐independent analgesia in various experimental pain models. To our knowledge, the constrained macrocycle in which the Ile12 residue of NT(7–12) was substituted by cyclopentylalanine, Pro7 and Pro10 were replaced by allyl‐glycine followed by side‐chain to side‐chain cyclization is the most selective analog targeting NTS2 identified to date (Ki 2.9 nM), showing 30,000‐fold selectivity over NTS1. Of particular importance, this macrocyclic analog is also able to potentiate the analgesic effects of morphine in a dose‐ and time‐dependent manner. Exerting complementary analgesic actions via distinct mechanisms of nociceptive transmission, NTS2‐selective macrocycles can therefore be exploited as opioid‐free analgesics or as opioid‐sparing therapeutics, offering superior pain relief with reduced adverse effects to pain patients.
- 1 June 2021
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 125, 168-192
Glial and neuroimmune cell choreography in sexually dimorphic pain signaling
- 1 June 2021
- Published by Elsevier in Neuroscience & Biobehavioral Reviews
- Vol. 125, 168-192
Glial and neuroimmune cell choreography in sexually dimorphic pain signaling